Mother Of Liveyon CEO Shares Heartfelt Stem Cell Success Story With Son On Pure Cast Podcast

Breaking from the traditional format of Liveyon’s live Pure Cast Podcast, Liveyon founder and CEO sat down with his mother, Lois Christianson, in a heartfelt conversation on how stem cell treatment saved her life after a horrifying injury.

While already suffering from severe arthritis, Lois tore her ACL/MCL meniscus—leaving her not only with excruciating pain but the thought of being wheelchair-bound for the rest of her life.

For Lois, the next few years looked worrisome. She grappled with the idea of how major surgery and years of physical therapy could still leave her reliant on canes and walkers. But Kosolcharoen, who launched Liveyon in 2016, told his mom to fly out to California for stem cell treatment instead. A doctor injected stem cells below her kneecap—and within 15 minutes, the severe pain was gone.

“Within a month or six weeks, I was walking pain-free two to three miles a day, and it just increased from there,” Lois said. “You know stem cells are real. I think they’re the way of the future, and I think regenerative medicine has a huge place in our aging population. It’s remarkable.”

But Lois’ connection to Liveyon doesn’t end with her remarkable recovery, as she continues to be an integral support system for John as a CEO and for the company.

She also played a major part in the rollout of Liveyon’s Pure® Product.

While the two sat in John’s office one afternoon, the good news arrived: After two years of hard work, compliance for Liveyon’s Pure® Product was complete and it was ready to launch.

“As the CEO and founder of Liveyon and Liveyon labs, I said ‘of course I want to be the first person that tries the new product, I’ll take the first flagship injection,’” Kosolcharoen said at the time.

But, just as John was there for his mother when she suffered her knee injury, she was there for him, too.

“I said ‘I have the least amount to lose, I’m the oldest and I believe this product is 100 percent pure,’” Lois recalled on the podcast. But if something is wrong, we can’t afford to lose our CEO, so I’ll be first.”

While regenerative medicine is still an experimental field, Liveyon has been a pioneer in the stem cell industry and manufacturer of the highly acclaimed Liveyon Pure® regenerative therapy umbilical cord stem cell product line.

The exclusive video series streams live every Monday, Wednesday and Friday morning and features John Kosolcharoen, founder and chief executive officer of Liveyon and Dr. Alan Gaveck, director of education, Liveyon. Dr. Gaveck brings 13 years of experience in both clinical and surgical medical treatments and the two hosts’ intellectual chemistry enhances the show’s format, as they tackle groundbreaking topics and introduce experts in the field of regenerative medicine, including leading researchers and physicians.

Founded in 2016, Liveyon is pushing the boundaries of regenerative medicine with its innovative take on product research and development, and distribution, and commitment to safety and transparency. Liveyon and Liveyon Labs Inc. are committed to achieving unparalleled stem cell potency through high live nucleated cell counts, while following validation protocols that produce an extremely consistent product for the most efficacious outcomes. The company’s dynamic ability to adapt to changing market trends and execute on opportunities has fortified its exponential growth and the company is poised to continue making a huge.

To stay up-to-date on the regenerative medicine industry and receive notices of free upcoming live streaming video events, please subscribe to Liveyon Pure Cast.

 

 

For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at:

 

 

Medical Professional Viewing Only (Disclaimer)</font color>


This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194655.htm
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm286155.htm
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.